The treatment, a cocktail of casirivimab and imdevimab, was granted FDA emergency use authorization in November.
When announcing the revision to its emergency approval, the FDA stipulated that the antibody cocktail is authorized as a COVID-19 prophylaxis only for individuals who have been exposed to the virus. The agency also said the treatment is not a substitute for a COVID-19 vaccine.
